Skip to main content
Full access
Letter
Published Online: 1 August 1999

Depression-Dependent Tardive Dyskinesia

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
SIR: Tardive dyskinesia (TD) is the most feared side effect of prolonged neuroleptic treatment, and some studies have found that the risk of developing TD is higher in patients with affective disorders.1 There are several theories about the etiology of TD, including dopamine receptor supersensitivity. On the other hand, there is evidence that depression is linked to a reduction in dopamine transmission. If that is so, then an improvement of previous TD could be expected in depressive episodes. Here, we report a case of a bipolar patient with TD during depressive episodes and remission during mania.

Case Report

Ms. A. was a 67-year-old woman with bipolar disorder. Her history of typical bipolar disorder started 23 years previously, when she was 44. Five years later, she began treatment with lithium. She had been admitted to the hospital on nine occasions. When she was not in a manic episode, she experienced a mildly depressed mood, with diminished interest and social withdrawal. Her family stated that she had not been euthymic in the last 20 years. She had been treated with antipsychotics during manic episodes, mainly with haloperidol 5–8 mg/day.
Three years before the last hospital admission, her family noticed orofacial movements while she was depressed. Examination during this admission (manic episode) revealed no abnormal movements. Two months later, she developed a mild depressive episode (Hamilton score=8) and showed choreoathetoid movements of the tongue and chewing-like movements. The Abnormal Involuntary Movement Scale (AIMS) summed score of items 1–7 was 7. She continued with lithium, and neuroleptic treatment was withdrawn. Three months later, she began to be energetic, became inappropriately flirtatious, increased her rate of speech, and decreased her hours of sleep. The abnormal movements disappeared before any change of treatment. Clonazepam (4 mg/day) was added without significant impact on the clinical features. Lithium was discontinued, and she began treatment on carbamazepine, up to 800 mg/day (blood level=8 μg/ml). She continued having manic symptoms, but without dyskinetic movements (AIMS score=1), and after 6 weeks she again returned to her mild depressive basal status. The patient was followed as an outpatient for a year. She was taking carbamazepine and occasionally zolpidem, and she continued with depressive symptoms and moderate chewing and tongue movements (AIMS score=6).

Discussion

The patient showed features of TD during depression and complete remission of these symptoms during mania. There are 4 cases with a similar pattern described in the literature. Cutler et al.2 reported 2 patients with dyskinesia during depression but not during mania; Sachdev3 reported a woman with a worsening of TD during depression and improvement on remission; and Sandyk4 studied a patient with bipolar illness in whom TD emerged concurrently with the onset of depression. The opposite finding (exacerbation of TD during mania) was found by Goswami et al.,5 and this would be more congruent with current theories of affective disorders and TD, since TD and mania are supposed to be associated with dopamine hyperactivity, whereas depression could be linked with dopamine hypoactivity.

References

1.
Ebadi M, Srinivasan SK: Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Pharmacol Rev 1995; 47:575–604
2.
Cutler NR, Post RM, Rey AC, et al: Depression-dependent dyskinesias in two cases of manic-depressive illness. N Engl J Med 1981; 304:1088–1089
3.
Sachdev PS: Depression-dependent exacerbation of tardive dyskinesia. Br J Psychiatry 1989; 155:253–255
4.
Sandyk R: Tardive dyskinesia associated with depression in a bipolar patient: possible role of melatonin. Int J Neurosci 1990; 52:79–83
5.
Goswami U, Narayanan HS, Channabasavanna SM: A study of state-dependent reversal of tardive dyskinesia: phenomenological probe in humans. J Clin Psychopharmacol 1985; 5:48–50

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 413 - 414
PubMed: 10440024

History

Published online: 1 August 1999
Published in print: August 1999

Authors

Affiliations

Jose Luis zquez-Barquero, Ph.D.
Santander, Spain

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share